Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2020-11-27 | Mary Tagliaferri, M.D., has been a director of the Company since November 17, 2020. Dr. Tagliaferri is currently a member of the Company’s Audit Committee. ... Dr. Tagliaferri has been serving as Senior Vice President and Executive Clinical Fellow for Nektar Therapeutics, a Nasdaq-listed company, since March 2020. |
| 2022-03-01 | Mary Tagliaferri, M.D., has been a director of the Company since November 17, 2020. Dr. Tagliaferri is currently Chair of the Company’s Board of Directors, chair of the Company’s Nominating/Governance Committee and a member of both the Company’s Audit Committee and Compensation Committee. |
| 2022-12-21 | Mary Tagliaferri, M.D., has been a director of the Company since November 2020 and Chair of the Board since January 2022. Dr. Tagliaferri is currently chair of the Company’s Nominating & Governance Committee and a member of both the Company’s Audit Committee and Compensation Committee. ... The following table sets forth the information concerning compensation earned during our fiscal year ended July 31, 2022 by all non-employee Directors: ... Mary Tagliaferri, M.D. $95,000 Fees Earned or Paid in Cash, $200,000 Restricted Stock Unit Awards, Total $295,000. |
Data sourced from SEC filings. Last updated: 2025-08-30